Lithium for Parkinson's: an extension trial
Part of Brain & nervous system clinical trials.
This trial extends a previous study to see if lithium can help Parkinson's symptoms. It's for people who already took part in a related study at the University at Buffalo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed one of the earlier Parkinson's studies (STUDY00007253 or STUDY00008239) at the University at Buffalo.
- No unstable heart, medical, nerve (like Parkinson's itself), or mental health problems that the study doctor thinks could be unsafe.
- No current use of illegal drugs or alcohol abuse as judged by the study doctor.
- No past brain surgery or need for brain surgery (including deep brain stimulation) within the next 24 weeks.
- If you can become pregnant, you need a negative pregnancy test and must use birth control (barrier method or hormonal).
- You must be willing to sign a consent form and follow the study's rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests a new treatment made from your own cells to replace damaged brain cells, aiming to improve movement and reduce symptoms. It's for people who have had Parkinson's for at least 4 years and respond well to levodopa.
This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.